I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

Key Takeaways Teen prescriptions for Wegovy rose 50% in 2024But many still can’t access the medication due to cost or ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic ...

Today marks the first official agency warning about the possibility of these drugs—specifically Mounjaro—decreasing the ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...